Key facts
- Inanovate’s last known valuation is $11.8M (Feb 2022).
- It has raised $10.1M across 9 recorded rounds; the latest was Seed Round ($808K) in Mar 2025.
- Notable investors include US National Science Foundation, Denny Sanford, National Cancer Institute, Sanford Frontiers, University of Birmingham.
- Inanovate has filed 9 Form Ds with the SEC since 2019, most recently Jul 2025 ($808K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 9 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Inanovate
Funding rounds
9 roundsAbout Inanovate
Developer of longitudinal assay screening technology designed for the detection and measurement of multiple proteins. The company's technology offers to test and benchmark Bio-ID which consists of a compact bench-top analyzer and disposable test cartridges for precisely measuring the concentration of multiple disease-related biological molecules from patient blood samples, helping patients to lower the cost and improve the accuracy of diagnostic tests.
- Sector
- Healthcare
- HQ
- Sioux Falls, SD, United States
- Founded
- 2006
- Employees
- 19
- Website
- inanovate.com/
- Ownership
- Privately Held (backing)
Inanovate doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inanovate shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inanovate in its N-PORT filings yet. We sweep new filings monthly.